MedPath
NMPA Approval

Cefprozil for Suspension

国药准字H20244104

June 25, 2024

Drug Information

头孢丙烯干混悬剂

口服混悬剂

0.25g(按C₁₈H₁₉N₃O₅S计)

化学药品

June 25, 2024

Company Information

Applicant Company

苏州市吴江区汾湖高新技术产业开发区金字路8号

Manufacturing Company

苏州市吴江区汾湖高新技术产业开发区金字路8号

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

头孢丙烯干混悬剂 - NMPA 批准文号 | MedPath